Type: Plasma from convalescent COVID-19 patients with specific antibodies, processed into a hyperimmune immunoglobulin Status: Grifols said October 9 that its anti-SARS-CoV-2 hyperimmune globulin had ...
Grifols, S.A. has executed a turnaround, with Q3 '25 results confirming improved fundamentals, reduced leverage, and restored dividend, supporting a renewed 'Buy' rating. GRFS now trades at a ...
Yahoo Finance UK: Assessing Grifols (BME:GRF) Valuation After Recent Share Price Weakness And Perceived Discount
Recent performance context for Grifols Grifols (BME:GRF) has drawn investor attention after a mixed run, with a modest 1 day gain, a negative move over the past week and month, and a deeper decline ...
Assessing Grifols (BME:GRF) Valuation After Recent Share Price Weakness And Perceived Discount
The Globe and Mail: Grifols Refinances 2027 Debt and Extends Maturities with Multi-Billion Term Loan B Package
Detailed price information for Grifols S.A. ADR (GRFS-Q) from The Globe and Mail including charting and trades.
Grifols Refinances 2027 Debt and Extends Maturities with Multi-Billion Term Loan B Package
Spanish plasma-derived medicines company Grifols announced that it has successfully completed the refinancing of its 2027 debt maturities through a new credit agreement structured as a Term Loan B ...
The Corner: Grifols plans to make early repayment of €500 million of its 7.5% secured bonds maturing in 2030
Link Securities | Grifols (GRF) plans to make an early repayment of €500 million of its 7.5% senior secured bonds maturing in 2030. This transaction would ...
Grifols plans to make early repayment of €500 million of its 7.5% secured bonds maturing in 2030